Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Gavo-cel Elicits Clinical Benefit in Solid Tumors, Including Ovarian Cancer and Mesothelioma

September 28th 2022

Gavocabtagene autoleucel demonstrated positive topline results from the phase 1 portion of a phase 1/2 trial in patients with mesothelin-expressing solid tumors.

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

September 28th 2022

Myung-Ju Ahn, MD, summarizes the role of neoadjuvant immunotherapy in early-stage NSCLC treatment.

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

September 28th 2022

Melissa Johnson, MD, and Solange Peters, MD, review the available treatment options for stage I – III non-small cell lung cancer (NSCLC) and how the ESMO guidelines of patient management differ from the NCCN guidelines.

FDA Approves Bevacizumab-adcd Biosimilar in Six Solid Tumors

September 28th 2022

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

Sunvozertinib Generates Responses in Platinum-Pretreated EGFR Exon 20–Mutated NSCLC

September 27th 2022

Sunvozertinib provided beneficial antitumor activity when used as a second- or later-line treatment in patients with non­­­–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy.

Pembrolizumab Plus Chemo Maintains Survival Benefit in Treatment-Naïve Nonsquamous NSCLC

September 27th 2022

Pembrolizumab plus platinum/pemetrexed continued to demonstrate an overall survival and progression-free survival benefit vs platinum/pemetrexed alone in patients with previously untreated, metastatic squamous non–small cell lung cancer.

Pembrolizumab Plus Chemotherapy Drives Durable PFS, OS Benefit in Squamous NSCLC

September 24th 2022

Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival and overall survival vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer regardless of PD-L1 expression level.

ODAC Votes Against Poziotinib for HER2 Exon 20 Insertion–Mutated NSCLC

September 22nd 2022

In a 9 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the benefits of poziotinib do not outweigh its risks for the treatment of patients with HER2 exon 20 insertion–mutated non–small cell lung cancer.

Frontline Toripalimab Plus Chemotherapy Approved in China for Advanced Nonsquamous NSCLC

September 20th 2022

The China National Medical Products Administration has approved the supplemental new drug application seeking the approval of toripalimab plus pemetrexed and platinum as a frontline treatment in unresectable, locally advanced or metastatic, nonsquamous non–small cell lung cancer not harboring EGFR mutations or ALK fusions.

HER2 Alterations in NSCLC: Clinical Scenario

September 20th 2022

Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

Liquid vs Solid Tumor Biopsies in NSCLC

September 20th 2022

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Changes Improve Radiation Therapy in SCLC

September 16th 2022

Investigators are making progress in delineating the optimal use of radiation therapy for the treatment of patients with small cell lung cancer, which remains a cornerstone of therapy for the malignancy, particularly in limited-stage disease.

Dr. Ip on the Utility of Carboplatin, Pemetrexed, and Pembrolizumab in Lung Adenocarcinoma

September 15th 2022

Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.

Progress on New Therapies Stirs Hope in SCLC

September 15th 2022

During the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.

Approaches to Biomarker Testing in NSCLC

September 12th 2022

Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

Biomarker Testing in NSCLC: Clinical Scenario

September 12th 2022

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

September 12th 2022

Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.

Trastuzumab Deruxtecan at Reduced Dose Maintains Efficacy in HER2-Mutated NSCLC

September 12th 2022

The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.

Sotorasib Significantly Improves PFS Vs Docetaxel for KRAS G12C–Mutated NSCLC

September 12th 2022

Sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of progression or death by 34% compared with docetaxel for patients with previously treated non–small cell lung cancer with KRAS G12C mutations.

Atezolizumab Shows Substantial OS Improvement in Platinum-Ineligible NSCLC

September 12th 2022

Atezolizumab led to an almost doubling in the rate of 2-year overall survival compared with vinorelbine or gemcitabine in patients with advanced platinum-ineligible non–small cell lung cancer.